JNY Stock Chart & Stats
€0.26
€0.00(0.00%)
At close: 4:00 PM EST
€0.26
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.16 - €0.61
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€90.06M
Enterprise Value€507.99
Total Cash (Recent Filing)€503.28M
Total Debt (Recent Filing)€262.67M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding416,729,430
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.68
Price to Sales (P/S)3.39
P/FCF Ratio-11.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)€34.57M
Bulls Say, Bears Say
Bulls Say
Revenue And Margin RecoveryThe strong revenue rebound and higher gross margin indicate improving commercial traction for the CAR-T portfolio. If sustained, better scale and product economics could support narrowing losses as the company expands commercialization.
Improved Cash UsageThe substantial reduction in operating cash burn suggests improved cost control or working-capital dynamics. Although cash generation remains negative, continued improvement could extend funding flexibility and reduce pressure during the path toward profitability.
Manageable LeverageModerate leverage means debt is not currently the primary balance-sheet constraint. This gives the company more flexibility to fund development and commercialization, although equity erosion and ongoing losses remain important financial risks.
Bears Say
Deep Ongoing LossesThe company remains far from operating break-even despite stronger revenue and gross margin. Persistent negative profitability limits internally generated funding, increases execution risk, and makes successful commercialization essential to improving long-term financial quality.
Persistent Negative Cash FlowRecurring negative operating and free cash flow indicates that the business is not yet self-funding. Unless revenue growth converts into sustainable profitability, JW Therapeutics may need external financing to support research, manufacturing, and commercial expansion.
Equity Base ErosionCumulative losses have weakened the capital base even though leverage remains manageable. Further erosion could reduce financial resilience and increase dependence on new capital, particularly if cash burn persists before the CAR-T business reaches profitability.
JW (Cayman) Therapeutics Co. Ltd. News
JNY FAQ
What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was €0.15 and its highest was €0.61 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
JW (Cayman) Therapeutics Co. Ltd.’s market cap is €90.06M.
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 209 days.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Aug 27, 2026. The company reported -€0.015 earnings per share for the quarter.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 416,729,430 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -€0.015 in its last earnings report. Following the earnings report the stock price went up 4.464%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in DE:JNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
Technical Analysis
Alphamab Oncology
―
CARsgen Therapeutics Holdings Ltd.
―
Mabpharm Limited
―
CStone Pharmaceuticals
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―